“And that should read out middle or second half of this year.”

In context

“lly powered should it be positive for overall survival. It will also be clinically meaningful. Just a reminder, we also have an ongoing Phase III trial in the TPS high, TPS more than 50. And data will be shared at ASCO from the Phase I experience. This is pembro versus pembro plus SV. A reminder that last year, we shared data for that combination in PD-L1 high handful of patients, but everyone responded in that population. So it was 100% response rate in a small population. And for mevrometostat, again, an important differentiated, highly specific differentiated EZH2. The first study that will read out is MEVPRO-1, which is in patients post abiraterone of significant unmet need and enzalutamide versus -- sorry, enzalutamide plus EZH2 versus physicians' choice of enzalutamide or docetaxel. And that should read out middle or second half of this year. Operator: Our next question comes from Chris Schott with JPMorgan. Christopher Schott: Maybe 2 for me. First, maybe for Dave or the broader team. I know you typically don't raise guidance with 1Q, but does seem like a very solid start to the year from a revenue perspective. Can you just talk generally about the business trends versus your expectations and just how you're thinking about the year progressing from here? And then second question for me was on BD capacity. You mentioned $7 billion. I guess just given the Vyndamax clarity, could the company look at larger transactions if the right deal were to present itself? Or is the focus still much more on the internal pipeline and maybe small tuck-ins from here? David Denton: Yes. Chris, Dave here. Thank you. Yes, I think to your first que”